Scholarlink

Introduction <p>In Thailand, obtaining medicines for rare diseases presents significant challenges, with limited evidence highlighting these issues.</p> Objectives <p>To evaluate the accessibility of medicines and the extent of health insurance coverage for treatments of rare diseases in Thailand.</p> Method <p>This study utilized a thorough review of current health policies, drug registration database, and insurance coverage conditions. Additionally, procurement data from the Ministry of Finance was analyzed to verify the acquisition of medicines intended for the treatment of rare diseases.</p> Results <p>A review of the availability and procurement of medicines for rare diseases in Thailand revealed considerable limitations in both registration and accessibility. According to the International Rare Diseases Research Consortium, only 46.80% of their recommended medicines were registered in Thailand, and of these, just 22.93% were included in the national essential medicines list. Additionally, a review of the state’s pharmaceutical procurement dataset over the past 5&#xa0;years showed that merely 31.70% of these registered drugs had been purchased from suppliers for use in hospitals.</p> Conclusion <p>To address these issues, the study recommended accelerating the approval process for rare disease medicines, expanding health insurance coverage, establishing financial support for patients, and creating a specific pricing policy for orphan drugs. Collaborative efforts among stakeholders were emphasized as crucial for improving access to essential medicines and enhancing treatment outcomes for patients with rare diseases in Thailand.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unlocking access: a comprehensive analysis of medicines accessibility for rare diseases in Thailand

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月28日

查看全文
  • Siriwat Suwattanapreeda,
  • Sanita Hirunrassamee,
  • Chaoncin Sooksriwong,
  • Kusawadee Maluangnon,
  • Thirapich Chuachantra,
  • Krissana Kuchaisit,
  • Niti Osirisakul

摘要

Introduction

In Thailand, obtaining medicines for rare diseases presents significant challenges, with limited evidence highlighting these issues.

Objectives

To evaluate the accessibility of medicines and the extent of health insurance coverage for treatments of rare diseases in Thailand.

Method

This study utilized a thorough review of current health policies, drug registration database, and insurance coverage conditions. Additionally, procurement data from the Ministry of Finance was analyzed to verify the acquisition of medicines intended for the treatment of rare diseases.

Results

A review of the availability and procurement of medicines for rare diseases in Thailand revealed considerable limitations in both registration and accessibility. According to the International Rare Diseases Research Consortium, only 46.80% of their recommended medicines were registered in Thailand, and of these, just 22.93% were included in the national essential medicines list. Additionally, a review of the state’s pharmaceutical procurement dataset over the past 5 years showed that merely 31.70% of these registered drugs had been purchased from suppliers for use in hospitals.

Conclusion

To address these issues, the study recommended accelerating the approval process for rare disease medicines, expanding health insurance coverage, establishing financial support for patients, and creating a specific pricing policy for orphan drugs. Collaborative efforts among stakeholders were emphasized as crucial for improving access to essential medicines and enhancing treatment outcomes for patients with rare diseases in Thailand.